Johnson & Johnson acquires robotic technology for $3.4B+: 5 things to know

Spinal Tech

Johnson & Johnson's Ethicon plans to acquire robotic technologies company Auris Health for $3.4 billion.

 

Five things to know:

1. Ethicon will pay around $3.4 billion in cash to acquire Auris, with additional contingent payments of up to $2.35 billion if the company reaches predetermined milestones.

2. Auris Health is a privately held robotic technologies company that currently focuses on lung cancer applications with a platform in brochoscopic diagnostic and therapeutic procedures.

3. The acquisition could accelerate Johnson & Johnson's entry into robotics, and the company left the door open for growth and expansion of robotics into other interventional applications. Johnson & Johnson previously acquired Orthotaxy's robotic technology for orthopedics and plans to continue developing the Verb Surgical Platform through its Verily partnership, seeing the Auris acquisition as complementary to its current robotic technology.

"We believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes," said Johnson & Johnson's Vice President, Worldwide Chairman, Medical Devices Ashley McEvoy.

4. Post-acquisition, Auris Founder and CEO Frederic Moll, MD, will join Johnson & Johnson.

5. This acquisition is part of Johnson & Johnson's plan to create a connected digital ecosystem that uses data to improve patient outcomes and leverages robotic technology. The transaction is expected to close during the second quarter.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers